<DOC>
	<DOCNO>NCT00006251</DOCNO>
	<brief_summary>This clinical trial study fludarabine phosphate , low-dose total-body irradiation , donor stem cell transplant follow cyclosporine , mycophenolate mofetil , donor lymphocyte infusion treat patient hematopoietic cancer . Giving low dos chemotherapy , fludarabine phosphate , total body irradiation ( TBI ) donor peripheral blood stem cell transplant help stop growth cancer cell . It may also keep patient 's immune response reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate , Low-Dose Total-Body Irradiation , Donor Stem Cell Transplant Followed Cyclosporine , Mycophenolate Mofetil , Donor Lymphocyte Infusion Treating Patients With Hematopoietic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate risk graft rejection associate addition fludarabine ( fludarabine phosphate ) non-myeloablative condition regimen patient malignant disease treatable allogeneic stem cell transplantation compare rate observe among patient previously treat without fludarabine . II . To estimate rate grade acute II/IV graft-vs-host disease ( GVHD ) chronic GVHD patient treat low-dose total-body irradiation ( TBI ) , fludarabine , peripheral blood stem cell ( PBSC ) infusion immunosuppression cyclosporine mycophenolate mofetil . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day - 4 -2 undergo low-dose TBI day 0 . ( Note : Patients autologous transplant within 90 day prior day 0 receive fludarabine phosphate . ) PBSC INFUSION : Patients undergo allogeneic PBSC transplant day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 35 taper day 56 . Patients receive mycophenolate mofetil PO BID day 0-27 . POST TRANSPLANT DONOR LYMPHOCYTE INFUSION ( DLI ) : Patients stable mixed chimerism day 56 , without evidence GVHD , undergo DLI IV 30 minute day 65 . Patients without complete response , full donor chimerism , GVHD 2 month undergo DLI high cell number . Up 6 DLIs may give 65 day apart . After completion study treatment , patient follow 4 , 6 , 12 , 18 24 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients age &gt; 49 year &lt; 75 year nonHodgkin lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) multiple myeloma eligible curative autologous transplantation fail prior autologous transplantation ; patient NHL CLL must fail prior therapy alkylating agent and/or fludarabine , high risk relapse ; patient multiple myeloma must stage II III disease receive prior chemotherapy Patients &lt; 50 year age NHL , CLL multiple myeloma high risk regimen relate toxicity prior autologous transplant preexist medical condition Patients &lt; 75 year age malignant diseases treatable allogeneic bone marrow transplant ( BMT ) preexist chronic disease affect kidney , liver , lung , heart consider high risk regimen relate toxicity use standard high dose regimen ; follow disease likely candidate : Myelodysplastic syndrome Myeloproliferative syndrome Acute Leukemia &lt; 10 % blast Amyloidosis Hodgkin 's disease Renal cell carcinoma Patients malignancies decline standard allograft may approve transplant follow presentation approval Fred Hutchinson Cancer Research Center ( FHCRC ) chimerism group DONOR : Human leukocyte antigen ( HLA ) genotypically phenotypically identical relate donor Donor must consent granulocyte colonystimulating factor ( GCSF ) administration leukopheresis Donor must adequate vein leukopheresis agree placement central venous catheter ( femoral , subclavian ) Age &lt; 75 year Eligible highpriority curative autologous transplant Patients rapidly progressive aggressive NHL unless minimal disease state Active central nervous system ( CNS ) involvement disease Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Patients human immunodeficiency virus ( HIV ) positive Cardiac ejection fraction &lt; 40 % Severe defect pulmonary function test ( defect currently categorize mild , moderate severe ) define pulmonary consultant , receive supplementary continuous oxygen Total bilirubin &gt; 2 x upper limit normal Serum glutamate pyruvate transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) 4 x upper limit normal Karnofsky score &lt; 50 Patients poorly control hypertension Patients renal failure eligible , however patient renal compromise ( serum creatinine great 2.0 ) likely compromise renal function may require hemodialysis ( may permanent ) due need maintain adequate serum cyclosporine level DONOR : Identical twin Age le 12 year Pregnancy Infection HIV Inability achieve adequate venous access Known allergy GCSF Current serious systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>